173 related articles for article (PubMed ID: 21167466)
1. [Sensorineural hearing loss evolution in Vogt-Koyanagi-Harada syndrome].
Rodríguez Rivera V; Garrigues HP; Gallego Pinazo R
Acta Otorrinolaringol Esp; 2011; 62(6):465-8. PubMed ID: 21167466
[TBL] [Abstract][Full Text] [Related]
2. [Vogt Koyanagi Harada syndrome. Report of a case with hearing loss, tinnitus, vertigo associated to uveitis].
Pino Rivero V; Pardo Romero G; Rodríguez Carmona M; Iglesias González RJ; del Castillo Beneyto F
An Otorrinolaringol Ibero Am; 2007; 34(3):281-5. PubMed ID: 17725172
[TBL] [Abstract][Full Text] [Related]
3. [Vogt-Koyanagi-Harada syndrome; a model of autoimmune neurosensory hypoacusia].
Ramos Macias A; Ruiz Martín F; Criado Martín D; Gómez González JL; González M
Acta Otorrinolaringol Esp; 1989; 40(3):247-50. PubMed ID: 2631893
[TBL] [Abstract][Full Text] [Related]
4. Auditory and vestibular manifestations of Vogt-Koyanagi-Harada disease.
Al Dousary S
J Laryngol Otol; 2011 Feb; 125(2):138-41. PubMed ID: 20880417
[TBL] [Abstract][Full Text] [Related]
5. Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease.
Caso F; Rigante D; Vitale A; Costa L; Bascherini V; Latronico E; Franceschini R; Cantarini L
Clin Rheumatol; 2015 Oct; 34(10):1817-20. PubMed ID: 25224382
[TBL] [Abstract][Full Text] [Related]
6. Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome.
Agarwal M; Ganesh SK; Biswas J
Ocul Immunol Inflamm; 2006 Dec; 14(6):333-9. PubMed ID: 17162603
[TBL] [Abstract][Full Text] [Related]
7. Sensorineural hearing loss in Vogt-Koyanagi-Harada syndrome.
Ondrey FG; Moldestad E; Mastroianni MA; Pikus A; Sklare D; Vernon E; Nusenblatt R; Smith J
Laryngoscope; 2006 Oct; 116(10):1873-6. PubMed ID: 17003710
[TBL] [Abstract][Full Text] [Related]
8. [Vogt-Koyanagi-Harada syndrome. Eight cases].
Alaoui FZ; Benamour S; El Kabli H; Amraoui A
Rev Med Interne; 2007 Apr; 28(4):250-4. PubMed ID: 17350144
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the clinical efficacy of two different immunosuppressive regimens in patients with chronic vogt-koyanagi-harada disease.
Cuchacovich M; Solanes F; Díaz G; Cermenati T; Avila S; Verdaguer J; Verdaguer JI; Carpentier C; Stopel J; Rojas B; Traipe L; Gallardo P; Sabugo F; Zanoli M; Merino G; Villarroel F
Ocul Immunol Inflamm; 2010 Jun; 18(3):200-7. PubMed ID: 20482399
[TBL] [Abstract][Full Text] [Related]
10. [Rare form of uveitis with neurological symptoms: the Vogt-Koyanagi-Harada uveomeningoencephalitic syndrome].
Kätterer C; Kaeser HE; Steiger U
Schweiz Med Wochenschr; 1992 Feb; 122(8):269-74. PubMed ID: 1542780
[TBL] [Abstract][Full Text] [Related]
11. [The Vogt-Koyanagi-Harada syndrome in 11-year-old girl].
Swiech-Zubilewicz A; Wróblewska E; Mańkowska A
Klin Oczna; 2005; 107(7-9):511-4. PubMed ID: 16417010
[TBL] [Abstract][Full Text] [Related]
12. A case presentation of an IgA nephropathy patient with Vogt-Koyanagi-Harada syndrome.
Zhang Q; Fan X; Tian M; Han H
BMC Nephrol; 2020 Jul; 21(1):272. PubMed ID: 32660433
[TBL] [Abstract][Full Text] [Related]
13. Vogt-Koyanagi-Harada syndrome associated with bilateral serous macular detachments responsive to immunomodulatory therapy.
Gallagher MJ; Yilmaz T; Foster CS
Ophthalmic Surg Lasers Imaging; 2009; 40(3):345-7. PubMed ID: 19485308
[No Abstract] [Full Text] [Related]
14. Vogt-Koyanagi-Harada Syndrome in a Group of Patients in Two Ophthalmology Referral Centers in Bogotá, Colombia.
Guayacán CL; Galindo-Mendez B; de-la-Torre A
Ocul Immunol Inflamm; 2018; 26(7):1123-1127. PubMed ID: 28910557
[TBL] [Abstract][Full Text] [Related]
15. [Vogt-Koyanagi-Harada disease complicated by subretinal neovessels].
Lepvrier-Guibal N; Korobelnik JF; Xuan TH
J Fr Ophtalmol; 1995; 18(4):305-11. PubMed ID: 7769166
[TBL] [Abstract][Full Text] [Related]
16. Prevalence, clinical characteristics, and causes of vision loss in children with Vogt-Koyanagi-Harada disease in South India.
Martin TD; Rathinam SR; Cunningham ET
Retina; 2010; 30(7):1113-21. PubMed ID: 20168275
[TBL] [Abstract][Full Text] [Related]
17. Subfoveal choroidal thickness after treatment of Vogt-Koyanagi-Harada disease.
Maruko I; Iida T; Sugano Y; Oyamada H; Sekiryu T; Fujiwara T; Spaide RF
Retina; 2011 Mar; 31(3):510-7. PubMed ID: 20948460
[TBL] [Abstract][Full Text] [Related]
18. Effect of the duration of immunomodulatory therapy on the clinical features of recurrent episodes in Vogt--Koyanagi--Harada disease.
Errera MH; Fardeau C; Cohen D; Navarro A; Gaudric A; Bodaghi B; Westcott M; LeHoang P
Acta Ophthalmol; 2011 Jun; 89(4):e357-66. PubMed ID: 21251241
[TBL] [Abstract][Full Text] [Related]
19. Management of ocular complications of Vogt-Koyanagi-Harada syndrome.
Perente I; Utine CA; Cakir H; Kaya V; Tutkun IT; Yilmaz OF
Int Ophthalmol; 2009 Feb; 29(1):33-7. PubMed ID: 17952373
[TBL] [Abstract][Full Text] [Related]
20. Vogt-Koyanagi-Harada syndrome in a 4-year old child.
Cunningham ET; Demetrius R; Frieden IJ; Emery HM; Irvine AR; Good WV
Am J Ophthalmol; 1995 Nov; 120(5):675-7. PubMed ID: 7485374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
